Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 2
1966 3
1967 2
1968 3
1969 1
1971 1
1974 2
1975 1
1976 4
1977 1
1978 2
1979 1
1980 3
1981 5
1982 4
1983 5
1984 2
1985 2
1986 4
1987 8
1988 12
1989 6
1990 9
1991 7
1992 10
1993 16
1994 23
1995 11
1996 8
1997 10
1998 11
1999 14
2000 11
2001 10
2002 12
2003 13
2004 8
2005 13
2006 9
2007 6
2008 11
2009 10
2010 19
2011 24
2012 21
2013 26
2014 31
2015 35
2016 24
2017 35
2018 35
2019 36
2020 41
2021 53
2022 35
2023 27
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

684 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: matsunaga y. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD. Wunderink RG, et al. Among authors: matsunaga y. Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058798 Clinical Trial.
Novel mediators of idiopathic pulmonary fibrosis.
Saito S, Deskin B, Rehan M, Yadav S, Matsunaga Y, Lasky JA, Thannickal VJ. Saito S, et al. Among authors: matsunaga y. Clin Sci (Lond). 2022 Aug 31;136(16):1229-1240. doi: 10.1042/CS20210878. Clin Sci (Lond). 2022. PMID: 36043396 Review.
SIZE-specific dose estimate for lower-limb CT.
Kobayashi M, Nishihara Y, Haba T, Matsunaga Y, Asada Y, Kobayashi S. Kobayashi M, et al. Among authors: matsunaga y. Phys Eng Sci Med. 2022 Dec;45(4):1183-1191. doi: 10.1007/s13246-022-01186-4. Epub 2022 Oct 31. Phys Eng Sci Med. 2022. PMID: 36315380
Prolyl isomerase Pin1 in metabolic reprogramming of cancer cells.
Nakatsu Y, Yamamotoya T, Ueda K, Ono H, Inoue MK, Matsunaga Y, Kushiyama A, Sakoda H, Fujishiro M, Matsubara A, Asano T. Nakatsu Y, et al. Among authors: matsunaga y. Cancer Lett. 2020 Feb 1;470:106-114. doi: 10.1016/j.canlet.2019.10.043. Epub 2019 Oct 31. Cancer Lett. 2020. PMID: 31678165 Review.
SIZE-SPECIFIC DOSE ESTIMATES IN FETAL COMPUTED TOMOGRAPHY.
Kobayashi M, Nishihara Y, Haba T, Matsunaga Y, Minami K, Asada Y. Kobayashi M, et al. Among authors: matsunaga y. Radiat Prot Dosimetry. 2022 May 13;198(6):339-348. doi: 10.1093/rpd/ncac045. Radiat Prot Dosimetry. 2022. PMID: 35482288
Development of Pin1 Inhibitors and their Potential as Therapeutic Agents.
Nakatsu Y, Matsunaga Y, Ueda K, Yamamotoya T, Inoue Y, Inoue MK, Mizuno Y, Kushiyama A, Ono H, Fujishiro M, Ito H, Okabe T, Asano T. Nakatsu Y, et al. Among authors: matsunaga y. Curr Med Chem. 2020;27(20):3314-3329. doi: 10.2174/0929867325666181105120911. Curr Med Chem. 2020. PMID: 30394205 Review.
Taste Characteristics of Various Amino Acid Derivatives.
Tanase R, Senda R, Matsunaga Y, Narukawa M. Tanase R, et al. Among authors: matsunaga y. J Nutr Sci Vitaminol (Tokyo). 2022;68(5):475-480. doi: 10.3177/jnsv.68.475. J Nutr Sci Vitaminol (Tokyo). 2022. PMID: 36310083 Free article.
684 results